Maltez F

Diagnosis of Pneumocystis pneumonia: evaluation of four serologic biomarkers

Autores: Antunes F, Badura R, CALDERÓN E. J., CALÉ S. S., DE BOER M. G., Esteves F, Maltez F, MARQUEZ-MARTIN E., Matos O, VAN DER REIJDEN T. J.
Ano de Publicação: 2015
Journal: Clinical microbiology and infection
Link: http://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(14)00111-6/abstract

This study aimed to assess the usefulness of (1–3)-β-d-glucan (BG), Krebs von den Lungen-6 antigen (KL-6), lactate dehydrogenase (LDH) and S-adenosyl methionine (SAM) as serologic biomarkers in the diagnosis of PCP.
Ler mais

Multicentre study highlighting clinical relevance of new high-throughput methodologies in molecular epidemiology of Pneumocystis jirovecii pneumonia

Autores: Antunes F, Badura R, BASSAT Q., CALDERÓN E. J., de Armas Y, de Sousa B, Esteves F, HUANG L., Maltez F, Matos O
Ano de Publicação: 2016
Journal: Clinical microbiology and infection
Link: https://www.ncbi.nlm.nih.gov/pubmed/27021425

Pneumocystis jirovecii causes severe interstitial pneumonia (PcP) in immunosuppressed patients. This multicentre study assessed the distribution frequencies of epidemiologically relevant genetic markers of P. jirovecii in different geographic populations from Portugal, the USA, Spain, Cuba and Mozambique, and the relationship between the molecular data and the geographical and clinical information, based on a multifactorial approach.
Ler mais

Baseline susceptibility of primary HIV-2 to entry inhibitors.

Autores: Antunes F, Barroso H, Bártolo I, Borrego P, Caixas U, Calado R, Cavaco-Silva P, Doroana M, Maltez F, Marcelino JM, Rocha C, Taveira N
Ano de Publicação: 2012
Journal: Antiviral Therapy
Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Baseline+susceptibility+of+primary+HIV-2+to+entry+inhibitors

BACKGROUND:
The baseline susceptibility of primary HIV-2 to maraviroc (MVC) and other entry inhibitors is currently unknown.
Ler mais

Resistance to antibody neutralization in HIV-2 infection occurs in late stage disease and is associated with X4 tropism.

Autores: Antunes F, Barroso H, Borrego P, Doroana M, Família C, Maltez F, Marcelino JM, Nilsson C, Quintas A, Taveira N
Ano de Publicação: 2012
Journal: Aids
Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Resistance+to+antibody+neutralization+in+HIV-2+infection+occurs+in+late+stage+disease+and+is+associated+with+X4+tropism

OBJECTIVES:
To characterize the nature and dynamics of the neutralizing antibody (NAb) response and escape in chronically HIV-2 infected patients.
Ler mais

Unraveling Mycobacterium tuberculosis genomic diversity and evolution in Lisbon, Portugal, a highly drug resistant setting

Autores: Clark TG, Coll F, Couto I, Hill-Cawthorne GA, Jordao L, Macedo R, Machado D, Mallard K, Maltez F, McNerney R, Pain A, Perdigão J, Portugal I, Silva C, Silva H, Viveiros M
Ano de Publicação: 2014
Journal: BMC Genomics
Link: http://www.biomedcentral.com/1471-2164/15/991

Multidrug- (MDR) and extensively drug resistant (XDR) tuberculosis (TB) presents a challenge to disease control and elimination goals. In Lisbon, Portugal, specific and successful XDR-TB strains have been found in circulation for almost two decades.
Ler mais

HIV-2 Integrase Polymorphisms and Longitudinal Genotypic Analysis of HIV-2 Infected Patients Failing a Raltegravir-Containing Regimen

Autores: Abecasis A, Aguas MJ, Almeida I, Camacho RJ, Cavaco-Silva J, Cunha C, Diniz A, Germano I, Gomes P, Gonçalves Mde F, Maltez F, Miranda AC, Narciso J, Poças J
Ano de Publicação: 2014
Journal: PLoS One
Link: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0092747

To characterize the HIV-2 integrase gene polymorphisms and the pathways to resistance of HIV-2 patients failing a raltegravir-containing regimen, we studied 63 integrase strand transfer inhibitors (INSTI)-naïve patients, and 10 heavily pretreated patients exhibiting virological failure while receiving a salvage raltegravir-containing regimen.
Ler mais